No Data
Dian Diagnostics Group Co.,Ltd.'s (SZSE:300244) Revenues Are Not Doing Enough For Some Investors
Dian Diagnostics Group (300244.SZ): Recently, the company's two data products have been listed on the Hangzhou Exchange.
On December 30, Gelonghui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that two of its data products, "Dian Diagnostics National Cervical Cancer Screening Positive Rate Analysis Data Report" and "Dian Diagnostics OCR Medical Testing Report Recognition Service," have been listed on the Hangzhou Exchange. This marks the company's first batch of data products that have achieved asset registration and are available for trading, taking an important step towards compliant trading of medical testing data products.
Dian Diagnostics Group (300244.SZ): The company's business has not yet involved Human Brain Engineering.
On December 23, Gelonghui丨Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that the company's Business has not yet involved Human Brain Engineering.
Dian Diagnostics Group (300244.SZ): The laboratory in Vietnam has successfully obtained the first comprehensive independent medical laboratory practice license issued by China for overseas operations.
On December 16, Glonghui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that its lab in Vietnam successfully obtained China's first comprehensive independent medical laboratory practice license overseas, and has entered normal and stable Operation. The company will further keep pace with the nation's Belt and Road Initiative Concept and, combining its own Business advantages, focus on conducting in-depth market research in the Middle East and Southeast Asia.
Dian Diagnostics Group (300244.SZ): The company's medical diagnostic services cover the maternal and child field and can provide a variety of infant-related testing items.
On December 16, Gelonghui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that the company has dedicated services and related products for infants and children. The company's medical diagnostic services cover maternal and child health, offering various related testing projects for infants and children. Additionally, the company can provide medical institutions with the necessary equipment, reagents, consumables, and technical support services for infant and child testing business.
Even After Rising 7.4% This Past Week, Dian Diagnostics GroupLtd (SZSE:300244) Shareholders Are Still Down 55% Over the Past Three Years
Dian Diagnostics GroupLtd (SZSE:300244) Adds CN¥362m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 41%
